AE Wealth Management LLC boosted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 17.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,757 shares of the pharmaceutical company’s stock after acquiring an additional 4,629 shares during the quarter. AE Wealth Management LLC’s holdings in GlaxoSmithKline were worth $1,240,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. We Are One Seven LLC lifted its holdings in shares of GlaxoSmithKline by 185.1% in the 1st quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 1,738 shares during the period. Kiley Juergens Wealth Management LLC purchased a new stake in shares of GlaxoSmithKline in the 2nd quarter worth $113,000. Adviser Investments LLC purchased a new stake in shares of GlaxoSmithKline in the 1st quarter worth $117,000. Toronto Dominion Bank lifted its holdings in shares of GlaxoSmithKline by 133.3% in the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after buying an additional 1,800 shares during the period. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of GlaxoSmithKline in the 2nd quarter worth $134,000. Institutional investors own 11.03% of the company’s stock.
In related news, insider Plc Glaxosmithkline purchased 148,818 shares of GlaxoSmithKline stock in a transaction dated Monday, July 30th. The stock was purchased at an average cost of $11.00 per share, with a total value of $1,636,998.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders bought 498,048 shares of company stock valued at $6,136,988. Corporate insiders own 10.00% of the company’s stock.
GSK has been the subject of several research reports. Argus upped their target price on GlaxoSmithKline from $45.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, August 20th. Shore Capital upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, July 27th. Zacks Investment Research cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, June 8th. Liberum Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. Finally, DZ Bank reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, June 14th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of $41.57.
GSK opened at $39.33 on Friday. The firm has a market capitalization of $96.69 billion, a PE ratio of 13.66, a P/E/G ratio of 1.93 and a beta of 0.86. The company has a debt-to-equity ratio of 8.13, a current ratio of 0.94 and a quick ratio of 0.61. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $42.36.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.47 billion. GlaxoSmithKline had a return on equity of 159.74% and a net margin of 5.51%. research analysts expect that GlaxoSmithKline plc will post 2.92 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 11th. Stockholders of record on Friday, August 10th will be given a $0.496 dividend. This represents a $1.98 annualized dividend and a dividend yield of 5.04%. The ex-dividend date of this dividend is Thursday, August 9th. GlaxoSmithKline’s payout ratio is 68.75%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.